Joel Palefsky, MD

Director of the ANCRE Center
Infectious Disease Specialist

Dr. Joel Palefsky is an expert in infectious diseases and cancers associated with these diseases. His expertise includes the treatment of anal dysplasia, a pre-cancerous condition that may lead to anal cancer and that is caused by the human papillomavirus (HPV). Anal dysplasia occurs in men and women and is especially common among patients infected with the human immunodeficiency virus (HIV). He also specializes in the biology and development of new treatments for HPV and Epstein-Barr virus.

Palefsky earned a medical degree at McGill University in Montreal, Canada and completed a fellowship in infectious disease at Stanford University. He is the founder and president of the International Anal Neoplasia Society and president-elect of the International Papillomavirus Society. He is a professor of medicine and laboratory medicine at UCSF.

Clinics

Anal Neoplasia Clinic, Research and Education (ANCRE) Center
1701 Divisadero, Suite 480
San Francisco CA 94115
Phone: (415) 353-7100
Fax: (415) 353- 4298

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Professor

More about Joel Palefsky

Additional Languages

French

Education

McGill University 1984

Residencies

McGill University, Internal Medicine 1984

Fellowships

Stanford University, Infectious Disease 1988

Selected Research and Publications

  1. Wechsler EI, Tugizov S, Herrera R, Da Costa M, Palefsky JM. E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line. J Gen Virol. 2018 Apr 06.
  2. Ortiz AP, González D, Vivaldi-Oliver J, Castañeda M, Rivera V, Díaz E, Centeno H, Muñoz C, Palefsky J, Joshipura K, Pérez CM. Periodontitis and oral human papillomavirus infection among Hispanic adults. Papillomavirus Res. 2018 Mar 16; 5:128-133.
  3. Ortiz AP, Tortolero-Luna G, Romaguera J, Pérez CM, González D, Muñoz C, González L, Marrero E, Suárez E, Palefsky JM, Panicker G, Unger ER. Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico. Papillomavirus Res. 2018 Mar 16; 5:109-113.
  4. Patel P, Bush T, Kojic EM, Conley L, Unger ER, Darragh TM, Henry K, Hammer J, Escota G, Palefsky JM, Brooks JT. Prevalence, Incidence, and Clearance of Anal High-Risk Human Papillomavirus Infection Among HIV-Infected Men in the SUN Study. J Infect Dis. 2018 Mar 05; 217(6):953-963.
  5. Somia IKA, Teeratakulpisarn N, Jeo WS, Yee IA, Pankam T, Nonenoy S, Trachuntong D, Mingkwanrungrueng P, Sukmawati MDD, Ramautarsing R, Nilasari H, Hairunisa N, Azwa I, Yunihastuti E, Merati TP, Phanuphak P, Palefsky J, Phanuphak N. Prevalence of and risk factors for anal high-risk HPV among HIV-negative and HIV-positive MSM and transgender women in three countries at South-East Asia. Medicine (Baltimore). 2018 Mar; 97(10):e9898.
  6. Pérez-Caraballo AM, Suarez E, Unger ER, Palefsky JM, Panicker G, Ortiz AP. Seroprevalence of Human Papillomavirus (HPV) Type 6, 11, 16, 18, by Anatomic Site of HPV Infection, in Women Aged 16-64 Years living in the Metropolitan Area of San Juan, Puerto Rico. P R Health Sci J. 2018 Mar; 37(1):26-31.
  7. Garland SM, Giuliano A, Brotherton J, Moscicki AB, Stanley M, Kaufmann AM, Bhatla N, Sankaranarayanan R, Palefsky JM, de Sanjose S. IPVS statement moving towards elimination of cervical cancer as a public health problem. Papillomavirus Res. 2018 Feb 27; 5:87-88.
  8. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, Doudna JA. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018 Feb 15.
  9. Kojic EM, Conley L, Bush T, Cu-Uvin S, Unger ER, Henry K, Hammer J, Escota G, Darragh TM, Palefsky JM, Brooks JT, Patel P. Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types covered by Current HPV Vaccines among HIV-Infected Women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (The SUN Study). J Infect Dis. 2018 Feb 14.
  10. Williamson AL, Garland S, Palefsky J, Rybicki E, Stanley M, de Sanjosé S. The Cape Town declaration on human papillomavirus related disease. Papillomavirus Res. 2017 Dec 30; 5:59-60.
  11. Dube Mandishora RS, Christiansen IK, Chin'ombe N, Duri K, Ngara B, Rounge TB, Meisal R, Ambur OH, Palefsky JM, Stray-Pedersen B, Chirenje ZM. Genotypic diversity of anogenital human papillomavirus in women attending cervical cancer screening in Harare, Zimbabwe. J Med Virol. 2017 Sep; 89(9):1671-1677.
  12. Garland SM, Brotherton JML, Moscicki AB, Kaufmann AM, Stanley M, Bhatla N, Sankaranarayanan R, de Sanjosé S, Palefsky JM. HPV vaccination of immunocompromised hosts. Papillomavirus Res. 2017 Dec; 4:35-38.
  13. Robbins HA, Strickler HD, Massad LS, Pierce CB, Darragh TM, Minkoff H, Keller MJ, Fischl M, Palefsky J, Flowers L, Rahangdale L, Milam J, Shrestha S, Colie C, D'Souza G. Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach. AIDS. 2017 Apr 24; 31(7):1035-1044.
  14. Raghavendran A, Hernandez AL, Lensing S, Gnanamony M, Karthik R, Sivasubramanian M, Kannangai R, Abraham P, Mathai D, Palefsky JM. Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men. Sex Transm Dis. 2017 03; 44(3):173-180.
  15. Kahn JA, Lee J, Belzer M, Palefsky JM. HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination. AIDS Behav. 2017 Feb 20.
  16. Wang CJ, Sparano J, Palefsky JM. Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. Surg Oncol Clin N Am. 2017 Jan; 26(1):17-31.
  17. Palefsky JM. Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era. Curr Opin HIV AIDS. 2017 Jan; 12(1):26-30.
  18. Sparano JA, Lee JY, Palefsky J, Henry DH, Wachsman W, Rajdev L, Aboulafia D, Ratner L, Fitzgerald TJ, Kachnic L, Mitsuyasu R. Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol. 2017 Mar; 35(7):727-733.
  19. Haga T, Efird JT, Tugizov S, Palefsky JM. Increased TNF-alpha and sTNFR2 levels are associated with high-grade anal squamous intraepithelial lesions in HIV-positive patients with low CD4 level. Papillomavirus Res. 2017 Jun; 3:1-6.
  20. Lee JY, Dhakal I, Casper C, Noy A, Palefsky JM, Haigentz M, Krown SE, Ambinder RF, Mitsuyasu RT. Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. J Cancer Epidemiol. 2016; 2016:2138259.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.